Response of glassy-cell carcinoma of the cervix to cisplatin, epirubicin, and mitomycin C

Mikio Mikami, Sachiko Ezawa, Naoko Sakaiya, Yuuki Komuro, Chisei Tei, Takeshi Fukuchi, Makio Mukai

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Among patients with uterine cervical cancer, glassy-cell carcinoma is very rare. The disease occurs mainly in younger patients, is rapidly progressive, and has a poor prognosis. We describe a case of glassy-cell carcinoma of the uterine cervix, in which preoperative intra-arterial chemotherapy was surprisingly effective.

Original languageEnglish
Pages (from-to)1159-1160
Number of pages2
JournalLancet
Volume355
Issue number9210
Publication statusPublished - 2000 Apr 1
Externally publishedYes

Fingerprint

Epirubicin
Mitomycin
Cisplatin
Cervix Uteri
Uterine Cervical Neoplasms
Carcinoma
Drug Therapy
Glassy cell carcinoma of the cervix

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Mikami, M., Ezawa, S., Sakaiya, N., Komuro, Y., Tei, C., Fukuchi, T., & Mukai, M. (2000). Response of glassy-cell carcinoma of the cervix to cisplatin, epirubicin, and mitomycin C. Lancet, 355(9210), 1159-1160.

Response of glassy-cell carcinoma of the cervix to cisplatin, epirubicin, and mitomycin C. / Mikami, Mikio; Ezawa, Sachiko; Sakaiya, Naoko; Komuro, Yuuki; Tei, Chisei; Fukuchi, Takeshi; Mukai, Makio.

In: Lancet, Vol. 355, No. 9210, 01.04.2000, p. 1159-1160.

Research output: Contribution to journalArticle

Mikami, M, Ezawa, S, Sakaiya, N, Komuro, Y, Tei, C, Fukuchi, T & Mukai, M 2000, 'Response of glassy-cell carcinoma of the cervix to cisplatin, epirubicin, and mitomycin C', Lancet, vol. 355, no. 9210, pp. 1159-1160.
Mikami M, Ezawa S, Sakaiya N, Komuro Y, Tei C, Fukuchi T et al. Response of glassy-cell carcinoma of the cervix to cisplatin, epirubicin, and mitomycin C. Lancet. 2000 Apr 1;355(9210):1159-1160.
Mikami, Mikio ; Ezawa, Sachiko ; Sakaiya, Naoko ; Komuro, Yuuki ; Tei, Chisei ; Fukuchi, Takeshi ; Mukai, Makio. / Response of glassy-cell carcinoma of the cervix to cisplatin, epirubicin, and mitomycin C. In: Lancet. 2000 ; Vol. 355, No. 9210. pp. 1159-1160.
@article{0bd03e7317b94eaf9479b3bf9e994e53,
title = "Response of glassy-cell carcinoma of the cervix to cisplatin, epirubicin, and mitomycin C",
abstract = "Among patients with uterine cervical cancer, glassy-cell carcinoma is very rare. The disease occurs mainly in younger patients, is rapidly progressive, and has a poor prognosis. We describe a case of glassy-cell carcinoma of the uterine cervix, in which preoperative intra-arterial chemotherapy was surprisingly effective.",
author = "Mikio Mikami and Sachiko Ezawa and Naoko Sakaiya and Yuuki Komuro and Chisei Tei and Takeshi Fukuchi and Makio Mukai",
year = "2000",
month = "4",
day = "1",
language = "English",
volume = "355",
pages = "1159--1160",
journal = "The Lancet",
issn = "0140-6736",
publisher = "Elsevier Limited",
number = "9210",

}

TY - JOUR

T1 - Response of glassy-cell carcinoma of the cervix to cisplatin, epirubicin, and mitomycin C

AU - Mikami, Mikio

AU - Ezawa, Sachiko

AU - Sakaiya, Naoko

AU - Komuro, Yuuki

AU - Tei, Chisei

AU - Fukuchi, Takeshi

AU - Mukai, Makio

PY - 2000/4/1

Y1 - 2000/4/1

N2 - Among patients with uterine cervical cancer, glassy-cell carcinoma is very rare. The disease occurs mainly in younger patients, is rapidly progressive, and has a poor prognosis. We describe a case of glassy-cell carcinoma of the uterine cervix, in which preoperative intra-arterial chemotherapy was surprisingly effective.

AB - Among patients with uterine cervical cancer, glassy-cell carcinoma is very rare. The disease occurs mainly in younger patients, is rapidly progressive, and has a poor prognosis. We describe a case of glassy-cell carcinoma of the uterine cervix, in which preoperative intra-arterial chemotherapy was surprisingly effective.

UR - http://www.scopus.com/inward/record.url?scp=0034176656&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034176656&partnerID=8YFLogxK

M3 - Article

VL - 355

SP - 1159

EP - 1160

JO - The Lancet

JF - The Lancet

SN - 0140-6736

IS - 9210

ER -